Abstract: The provided is a T-BsAb (T-cell-engaging bispecific antibody) with dual affinities to CD3 on T cells and CD19 on B cells and use thereof in treating autoimmune diseases. In particular, the provided is a PEGylated T-BsAb with dual affinities to CD3 and CD19 and use thereof in treating multiple sclerosis (MS) as well as other autoimmune diseases.

Abstract: Provided in embodiments of this application are a transmission assembly and a foldable electronic device. The transmission assembly includes a first transmission assembly. The first transmission assembly is configured for use in a bending area of the foldable electronic device. The first transmission assembly includes at least two first conductive layers and a first transmission layer located between the two first conductive layers. Each first conductive layer includes at least a first conductive fabric, and the first transmission layer includes at least one first signal line. A dielectric layer is further arranged between the first conductive layer and the first transmission layer, and the dielectric layer includes at least a first substrate layer.

Abstract: Provided are bispecific molecules and, in particular, long acting bispecific T cell engagers targeting CD3 and CD47 with improved efficacy, toxic profile and therapeutic window, and methods of making and using such long acting bispecific binding molecules.

Abstract: The invention discloses a method and application for a safe recovery of waste anode pieces of lithium ion batteries. The method comprises the following steps: crushing and sieving the waste anode piece to obtain an anode powder A and a crushed aluminum slag; mixing the crushed aluminum slag with an acid solution, stirring under ultrasound, and then performing wet sieving to obtain an aluminum slag and a battery powder; the obtained aluminum slag is washed with water, then rinsed with an explosion suppressant, centrifuging to obtain an explosion suppressing aluminum slag, and then packed and compressed to obtain an aluminum slag block; connecting the two ends of the aluminum slag block to a positive plate and a negative plate of a DC electrode respectively, applying a current to melt the aluminum slag block, and cooling to obtain a safe aluminum slag block.

Abstract: The present invention discloses a method for power battery automatic fine-quantity sorting and an apparatus thereof, the method including the following steps of S1. The material is crushed, and leveled, and is then subjected to magnetic sorting processing to sort out iron powder; S2. The material after magnetic sorting is subjected to electrostatic processing to sort out positive electrode material powder; S3. The material after electrostatic processing is subjected to bounce processing to sort out the collector and graphite powder. A magnetic sorting device, an electrostatic sorting device, and a bouncing sorting device are accordingly provided.

Abstract: The present invention discloses a method for power battery automatic fine-quantity sorting and an apparatus thereof, the method including the following steps of Si. The material is crushed, and leveled, and is then subjected to magnetic sorting processing to sort out iron powder; S2. The material after magnetic sorting is subjected to electrostatic processing to sort out positive electrode material powder; S3. The material after electrostatic processing is subjected to bounce processing to sort out the collector and graphite powder. A magnetic sorting device, an electrostatic sorting device, and a bouncing sorting device are accordingly provided.

Abstract: A medicament for treating hypertension is provided. The medicament has an active ingredient including cannabidiol or a pharmaceutically acceptable salt or ester thereof, and ligustrazine or a pharmaceutically acceptable salt or ester thereof is added to the active ingredient of the medicament. The medicament provided by the present invention has a good therapeutic effect on hypertension and can achieve a significant antihypertensive effect after being administered for a short time. The medicament for treating hypertension provided by the present invention has the advantages of low cost, low toxicity, stable chemical components, and continuous and stable antihypertensive effect.

Abstract: Provided herein is an antibody-drug conjugate (ADC) especially a PEGylated mono or bispecific antibody-drug conjugate (BsADC) prepared with site-specific conjugation to provide homogeneous conjugate with high potency and low toxicity. It also relates to a method for the preparation of the ADC, a composition comprising the ADC, and the use thereof in treating diseases.

Abstract: A long acting modified T-cell engager bispecific antibody with cytokine caps that provides reduced toxicity and boosted anti-tumor activity is disclosed. Method of making the modified and cytokine capped Bi-specific T-cell engager antibody is also disclosed.

Abstract: A terminal includes: a first baseband processor, a second baseband processor, a first radio frequency chip, a second radio frequency chip, a first antenna, a second antenna, a third antenna, and a fourth antenna. The first baseband processor is connected to the first antenna and the second antenna by using the first radio frequency chip. The first radio frequency chip is connected to the first antenna to form a first channel, and is connected to the second antenna to form a second channel. The second baseband processor is connected to the third antenna and the fourth antenna by using the second radio frequency chip. The second radio frequency chip is connected to the third antenna to form a third channel, and is connected to the fourth antenna to form a fourth channel.

Abstract: A terminal includes: a first baseband processor, a second baseband processor, a first radio frequency chip, a second radio frequency chip, a first antenna, a second antenna, a third antenna, and a fourth antenna. The first baseband processor is connected to the first antenna and the second antenna by using the first radio frequency chip. The first radio frequency chip is connected to the first antenna to form a first channel, and is connected to the second antenna to form a second channel. The second baseband processor is connected to the third antenna and the fourth antenna by using the second radio frequency chip. The second radio frequency chip is connected to the third antenna to form a third channel, and is connected to the fourth antenna to form a fourth channel.

Abstract: A terminal includes a first baseband processor, a second baseband processor, a first radio frequency chip, a second radio frequency chip, a first antenna, a second antenna, a third antenna, and a fourth antenna. The first baseband processor is coupled to the first antenna and the second antenna using the first radio frequency chip. The first radio frequency chip is coupled to the first antenna to form a first channel, and is coupled to the second antenna to form a second channel. The second baseband processor is coupled to the third antenna and the fourth antenna using the second radio frequency chip. The second radio frequency chip is coupled to the third antenna to form a third channel, and is coupled to the fourth antenna to form a fourth channel.

Abstract: A terminal includes a first baseband processor, a second baseband processor, a first radio frequency chip, a second radio frequency chip, a first antenna, a second antenna, a third antenna, and a fourth antenna. The first baseband processor is coupled to the first antenna and the second antenna using the first radio frequency chip. The first radio frequency chip is coupled to the first antenna to form a first channel, and is coupled to the second antenna to form a second channel. The second baseband processor is coupled to the third antenna and the fourth antenna using the second radio frequency chip. The second radio frequency chip is coupled to the third antenna to form a third channel, and is coupled to the fourth antenna to form a fourth channel.

Abstract: The present invention describes a dissociated cell culture system comprising cells of the hippocampus, one of the brain areas affected by Alzheimer's Disease (AD) or amyloid beta-related diseases. This culture system comprises hippocampal neuronal and glial cells from animal models of AD, particularly, but not limited to, double transgenic mice expressing both the human APP mutation (K670N:M671L) (mAPP), and the human PS1 mutation (M146L) (mPS1), and serves as a powerful tool for the screening and testing of compounds and substances, e.g., drugs, for their ability to affect, treat, or prevent AD or ?-amyloid-related diseases. The effects of a test substance on the cells in this culture system can be quantitatively assessed to determine if the test substance affects the cells biochemically and/or electrophysiologically, and/or optically, and/or immunocytochemically. The present in vitro culture system is advantageous for AD drug screening, because it is rapid and efficient.